Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

CRISPR THERAPEUTICS Aktie

 >Aktienkurs 
43.68 EUR    -5.0%    (TradegateBSX)
Ask: 43.865 EUR / 0 Stück
Bid: 43.74 EUR / 0 Stück
Tagesumsatz: 1901 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -8,3%
1 Monat: -3,8%
3 Monate: +3,5%
6 Monate: -6,4%
1 Jahr: -26,0%
laufendes Jahr: -5,5%
>CRISPR THERAPEUTICS Aktie
Name:  CRISPR THERAPEUTICS
Land:  Schweiz
Sektor:  Gesundheit
ISIN/ Wkn:  CH0334081137 / A2AT0Z
Symbol/ Ticker:  1CG (Frankfurt) / CRSP (NASDAQ)
Kürzel:  FRA:1CG, ETR:1CG, 1CG:GR, NASDAQ:CRSP
Index:  -
Webseite:  https://crisprtx.com/
Profil:  CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, re..
>Volltext..
Marktkapitalisierung:  4432.37 Mio. EUR
Unternehmenswert:  3050.32 Mio. EUR
Umsatz:  11.92 Mio. EUR
EBITDA:  -456.61 Mio. EUR
Nettogewinn:  -401.4 Mio. EUR
Gewinn je Aktie:  -4.24 EUR
Schulden:  697.34 Mio. EUR
Liquide Mittel:  259.55 Mio. EUR
Operativer Cashflow:  -328.83 Mio. EUR
Bargeldquote:  17.79
Umsatzwachstum:  -63.7%
Gewinnwachstum:  0.53%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  4 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.224.675 Euro.
Suchwörter:  CRISPR THERAPEUTICS
Letzte Datenerhebung:  17.10.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 96.69 Mio. St.
Frei handelbar: 92.84%
Rückkaufquote: -20.32%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 68.56%
Bewertung:
KGV: -
KGV lG: -
KUV: 359.85
KBV: 2.78
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -1510.66%
Gewinnmarge: -3368.72%
Operative Marge: -3971.53%
Managementeffizenz:
Gesamtkaprendite: -19.28%
Eigenkaprendite: -26.09%
>Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Stoffwechselerkrankungen (Diabetes/ Adipositas), Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
17.10.26 - 01:45
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
 
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close....
17.10.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Crispr Therapeutics im Wert von 720373 USD (Insiderkauf)
 
George, Simeon - Aufsichtsrat - Tag der Transaktion: 2026-10-14...
16.10.26 - 01:01
Insiderhandel: General Counsel and Secretary verkauft Aktien von Crispr Therapeutics im Wert von 51230 USD (Insiderkauf)
 
Kasinger, James R. - Vorstand - Tag der Transaktion: 2026-10-14...
16.10.26 - 01:01
Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 201867 USD (Insiderkauf)
 
Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2026-10-14...
13.10.26 - 01:45
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know (Zacks)
 
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day....
09.10.26 - 16:24
Citi Sees 60% Upside in CRISPR Therapeutics. Here′s What Has to Go Right. (Fool)
 
Most of any gains (or lack thereof) from here will be driven by just three factors....
09.10.26 - 02:02
Insiderhandel: General Counsel and Secretary verkauft Aktien von Crispr Therapeutics im Wert von 119481 USD (Insiderkauf)
 
Kasinger, James R. - Vorstand - Tag der Transaktion: 2026-10-06...
08.10.26 - 14:33
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 (GlobeNewswire EN)
 
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026....
07.10.26 - 01:45
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
 
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close....
05.10.26 - 16:45
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? (Zacks)
 
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...
02.10.26 - 16:18
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire EN)
 
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026....
29.09.26 - 11:24
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? (Fool)
 
The company will be judged by the results of its peers, and it might not compare as well as shareholders hope....
26.09.26 - 01:46
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here′s Why (Zacks)
 
CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close....
25.09.26 - 05:01
Insiderhandel: General Counsel and Secretary verkauft Aktien von Crispr Therapeutics im Wert von 626460 USD (Insiderkauf)
 
Kasinger, James R. - Vorstand - Tag der Transaktion: 2026-09-22...
24.09.26 - 15:24
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles....
23.09.26 - 14:24
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon (24/7 Wall St.)
 
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story....
23.09.26 - 01:45
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know (Zacks)
 
CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day....
22.09.26 - 05:02
Insiderhandel: Aufsichtsrat verkauft Aktien von Crispr Therapeutics im Wert von 780935 USD (Insiderkauf)
 
Behbahani, Ali - Aufsichtsrat - Tag der Transaktion: 2026-09-17...
20.09.26 - 18:24
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 (Fool)
 
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up....
18.09.26 - 05:24
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? (Fool)
 
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer andere von einer Wahrheit überzeugen will, der muß mit den Suchenden suchen und leiden. - Luise Rinser
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!